NO964915L - Transdermal avlevering av antiepileptiske legemidler - Google Patents

Transdermal avlevering av antiepileptiske legemidler

Info

Publication number
NO964915L
NO964915L NO964915A NO964915A NO964915L NO 964915 L NO964915 L NO 964915L NO 964915 A NO964915 A NO 964915A NO 964915 A NO964915 A NO 964915A NO 964915 L NO964915 L NO 964915L
Authority
NO
Norway
Prior art keywords
transdermal delivery
antiepileptic drugs
delivery system
antiepileptic
drugs
Prior art date
Application number
NO964915A
Other languages
English (en)
Other versions
NO964915D0 (no
Inventor
Helle Weibel
Peter Bonne Eriksen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8095138&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO964915(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO964915D0 publication Critical patent/NO964915D0/no
Publication of NO964915L publication Critical patent/NO964915L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Transdermalt avleveringssystem som inneholder tiagabin eller dets farmasøytisk akseptable salter eller estere, er beskrevet. Avleverings- systemet kan anvendes ved behandling av epilepsi.
NO964915A 1994-05-20 1996-11-19 Transdermal avlevering av antiepileptiske legemidler NO964915L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK57794 1994-05-20
PCT/DK1995/000194 WO1995031976A1 (en) 1994-05-20 1995-05-17 Transdermal delivery of anti-epileptic drugs

Publications (2)

Publication Number Publication Date
NO964915D0 NO964915D0 (no) 1996-11-19
NO964915L true NO964915L (no) 1996-11-19

Family

ID=8095138

Family Applications (1)

Application Number Title Priority Date Filing Date
NO964915A NO964915L (no) 1994-05-20 1996-11-19 Transdermal avlevering av antiepileptiske legemidler

Country Status (20)

Country Link
US (1) US5750140A (no)
EP (1) EP0760656A1 (no)
JP (1) JPH10500415A (no)
KR (1) KR970703146A (no)
CN (1) CN1148806A (no)
AU (1) AU698131B2 (no)
BR (1) BR9507736A (no)
CA (1) CA2190837C (no)
CZ (1) CZ338196A3 (no)
FI (1) FI964619A (no)
HU (1) HUT75864A (no)
IL (1) IL113793A (no)
NO (1) NO964915L (no)
NZ (1) NZ287012A (no)
PE (1) PE2596A1 (no)
RU (1) RU2152784C1 (no)
SK (1) SK281076B6 (no)
TW (1) TW372875B (no)
WO (1) WO1995031976A1 (no)
ZA (1) ZA954118B (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914333A (en) * 1996-07-31 1999-06-22 Novo Nordisk A/S Treatment of psychotic disorders
GB9712271D0 (en) * 1997-06-12 1997-08-13 Procter & Gamble Cosmetic composition
GB9712272D0 (en) * 1997-06-12 1997-08-13 Procter & Gamble Cosmetic composition
US6537537B2 (en) 1997-06-12 2003-03-25 The Procter & Gamble Company Water-in-silicone emulsion cosmetic compositions
US6316010B2 (en) 1997-06-12 2001-11-13 The Procter & Gamble Company Cosmetic compositions
GB9712269D0 (en) * 1997-06-12 1997-08-13 Procter & Gamble Cosmetic composition
EP0991409B1 (en) * 1997-08-01 2002-01-30 ELAN CORPORATION, Plc Controlled release pharmaceutical compositions containing tiagabine
IE970588A1 (en) 1997-08-01 2000-08-23 Elan Corp Plc Controlled release pharmaceutical compositions containing tiagabine
FR2771292B1 (fr) * 1997-11-21 2000-02-18 Ethypharm Lab Prod Ethiques Spheroides contenant de la tiagabine, procede de preparation et compositions pharmaceutiques
WO2003080072A1 (en) * 2002-03-18 2003-10-02 Cady Roger K Preemptive prophylaxis of migraine
TWI783890B (zh) 2017-08-24 2022-11-11 丹麥商諾佛 儂迪克股份有限公司 Glp-1組成物及其用途
CA3165359A1 (en) 2020-02-18 2021-07-22 Dorthe Kot Engelund Glp-1 compositions and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2105990B (en) * 1981-08-27 1985-06-19 Nitto Electric Ind Co Adhesive skin patches
SE8904296D0 (sv) * 1989-12-21 1989-12-21 Pharmacia Ab Transdermal system
DK58291D0 (da) * 1991-04-02 1991-04-02 Novo Nordisk As Krystalinsk stof og dets fremstilling

Also Published As

Publication number Publication date
JPH10500415A (ja) 1998-01-13
AU2559995A (en) 1995-12-18
NZ287012A (en) 1998-09-24
HUT75864A (en) 1997-05-28
FI964619A0 (fi) 1996-11-19
IL113793A (en) 1999-12-31
CZ338196A3 (en) 1997-06-11
EP0760656A1 (en) 1997-03-12
CN1148806A (zh) 1997-04-30
SK281076B6 (sk) 2000-11-07
CA2190837C (en) 2005-08-02
BR9507736A (pt) 1997-08-19
SK148296A3 (en) 1997-06-04
CA2190837A1 (en) 1995-11-30
AU698131B2 (en) 1998-10-22
RU2152784C1 (ru) 2000-07-20
ZA954118B (en) 1996-11-19
NO964915D0 (no) 1996-11-19
IL113793A0 (en) 1995-08-31
PE2596A1 (es) 1996-02-12
WO1995031976A1 (en) 1995-11-30
KR970703146A (ko) 1997-07-03
US5750140A (en) 1998-05-12
FI964619A (fi) 1996-11-19
TW372875B (en) 1999-11-01
HU9603206D0 (en) 1997-01-28

Similar Documents

Publication Publication Date Title
BR9801008A (pt) Formulação aerossol adequada para terapia, profilaxia ou contenção de infecções da mycobacterium tuberculosis de um pacientes sofrendo de tuberculose
HUP9800467A3 (en) Use of hyaluronic acid for producing pharmaceutical compns. for the treatment of interstitial cystitis
ATE321529T1 (de) Dosierungsform für eine verzögerte und zunehmende wirkstoffsfreisetzung
DE69333607D1 (de) Vorrichtung zur Herstellung von vorgefüllten, sterilen Abgabevorrichtungen
NO964915L (no) Transdermal avlevering av antiepileptiske legemidler
PT867184E (pt) Utilizacao de tiagabina para o tratamento de desordens do sono
NO954996D0 (no) Anvendelse av nona- og dekapeptider for fremstilling av et legemiddel for behandling av AIDS
DE69113386D1 (de) Herstellung von Medikamenten zur Behandlung von Asthma, unter Verwendung von (S)-Alpha-Fluoromethyl-Histidin und dessen Estern.
WO1997003188A3 (de) Verwendung von mp52 oder mp121 zur behandlung und prävention von erkrankungen des nervensystems
AU6528400A (en) Triple drug therapy for the treatment of narcotic and alcohol withdrawal symptoms
CA2120062A1 (en) Use of Sulodexide and of Medicines Containing It in the Treatment of Diabetic Nephropathy
MY117918A (en) Use of an h+, k+- atpase inhibitor in the treatment of nasal polyps
GB9521608D0 (en) Pharmaceutical composition
WO1997009317A3 (en) Optically active phenyl pyrimidine derivative as analgesic agent
NO990450L (no) Behandling av sinnslidelser
EP1447090B8 (de) Verwendung von Hyaluronidase zur Prophylaxe und Behandlung von Herz-Kreislauf-Erkrankungen
NO953003L (no) Anvendelse av ifenprodil og diastereoisomerer derav for fremstilling av medisinske preparater
ZA989665B (en) The use of glycosaminoglycans for producing pharmaceutical preparations for treating eye disorders associated with diabetes.
AU7500200A (en) Combined therapies for atherosclerosis treatment
DE60006284D1 (de) Arzneimittel zur behandlung konvulsivischer zustände
NO981320L (no) Oral anvendelse av (+)-O-demetyltramadol som smertemiddel
FR2818147B1 (fr) Nouvelle application therapeutique d'un derive de la thienyclyclohexylamine
ES2111890T3 (es) Empleo del acil l-carnitina gamma-hidroxibutirato para el tratamiento de la drogadiccion.
RU2002135306A (ru) Способ лечения гнойных ран
WO2000067733A3 (de) Medikament zur therapie der männlichen infertilität

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application